論文 - 山上　亘

Elevated ¹⁸F-FDG uptake in non-metastatic lymph nodes of POLE-mutated endometrial cancer on PET/CT

Kurihara M, Iwabuchi Y, Yamada Y, Shimizu A, Yoshimura T, Sakai K, Chiyoda T, Nakamura K, Nishihara H, Yamagami W, Jinzaki M

Eur J Radiol 195   112620 - 112620 2026年02月

研究論文（学術雑誌）, 共著

Prognostic Biomarker of Fertility- Preserving Hormonal Therapy Based on Multigene Panel Testing for Endometrial Cancer

Hirano T, Sakai K, Yoshimura T, Chiyoda T, Nakamura K, Aimono E, Kawaida M, Nishihara H, Susumu N, Aoki D, Yamagami W

Cancer Sci 117 （ 1 ） 236 - 245 2026年01月

研究論文（学術雑誌）, 共著

Efficient expansion of tumor-infiltrating lymphocytes from gynecologic cancer.

Matsukawa T, Ouchida T, Hayakawa T, Yoshikawa T, Ito Y, Kasuya H, Umehara C, Inoue S, Chiyoda T, Nishio H, Yamagami W, Hosoda W, Suzuki S, Kagoya Y

Journal of immunology (Baltimore, Md. : 1950) 214 （ 12 ） 3618 - 3633 2025年12月

ISSN  0022-1767

• Access to Document (DOI)

Impact of neoadjuvant chemotherapy followed by interval debulking surgery on survival in women with advanced non-serous ovarian, fallopian tube, or primary peritoneal cancer

Machida H., Kawana K., Okamoto A., Yamagami W., Mandai M., Kajiyama H., Nomura H., Mikami M.

Gynecologic Oncology 203   8 - 15 2025年12月

ISSN  00908258

　概要を見る

Objective: To evaluate the survival impact of neoadjuvant chemotherapy followed by interval debulking surgery (NACT/IDS) versus primary debulking surgery (PDS) in patients with advanced epithelial ovarian cancer of non–high-grade serous carcinoma (HGSC) histology. Methods: A retrospective analysis was conducted using the Japan Society of Obstetrics and Gynecology tumor registry (2017 to 2022). Patients with FIGO stage III–IV ovarian, fallopian tube, or primary peritoneal cancer were classified by histology (HGSC or non-HGSC), and compared initial treatment. Overall survival (OS) was analyzed using multivariate Cox proportional hazard model and propensity score matching (PSM). Results: Among 20,212 eligible cases, 14,718 (72.8 %) were HGSC and 5494 (27.2 %) were non-HGSC, primarily clear cell (2389;11.8 %) and endometrioid (1431;7.1 %) carcinomas. In HGSC patients, 7118 (48.4 %) received NACT, while in non-HGSC, 1203 (21.9 %) received NACT. Compared with HGSC, non-HGSC patients were younger, more frequently registered in eastern Japan, diagnosed at FIGO 2014 stage IIIA/IIIB, and underwent PDS and nodal evaluation (all, P < .05). In the overall cohort, non-HGSC histology was independently associated with poorer OS (adjusted-hazard ratio [HR]1.35, P < .001). Upstaging/IDS failure was higher in non-HGSC (36 %) vs HGSC (25 %, P < .001). After PSM, 5-year OS was comparable between HGSC patients who achieved IDS after NACT and those who underwent PDS (36.8 % vs 35.6 %; HR0.83, P = .12), whereas IDS failure was associated with markedly worse survival (3.9 %; HR3.12, P < .001). Conclusion: In non-HGSC, the rate of upstaging/IDS failure after NACT reached approximately 36 %; however, achieving IDS after NACT resulted in survival comparable to PDS, highlighting the need to select appropriate candidates.

• Access to Document (DOI)

当院で異型ポリープ状腺筋腫に対し子宮鏡手術により子宮温存可能であった28例の検討

金澤紀徳，坂井健良，落合大輔，坂巻智美，地阪光代，吉浜智子，大木慎也，千代田達幸，山上 亘

日本子宮鏡研究会雑誌 7 （ 1 ） 33 - 38 2025年12月

研究論文（学術雑誌）, 共著

Characteristics of endometrial cancer progressed to extrauterine lesions following fertility preserving medroxyprogesterone acetate therapy for young endometrial cancer patients

Kitazawa S, Sakai K, Kawaida M, Chiyoda T, Nishio H, Banno K, Susumu N, Yamagami W

J Gynecol Oncol 36 （ 6 ） e104 2025年11月

研究論文（学術雑誌）, 共著, 査読有り

Annual Report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2022 and Annual Treatment Report for 2017

Kajiyama H., Tamauchi S., Takahashi F., Satoh T., Satoh T., Yokoyama Y., Ishikawa M., Isobe M., Kajiyama H., Kanao H., Kawana K., Komatsu H., Sekine M., Fujiwara H., Matsumura N., Yamagami W., Watari H.

Journal of Obstetrics and Gynaecology Research 51 （ 11 ）  2025年11月

ISSN  13418076

　概要を見る

Aim: To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2022 and the Annual Treatment Report for 2017, on the outcomes of patients who started treatment in 2017. Methods: The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry, where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment with gynecologic malignancies was initiated in 2022 were analyzed retrospectively. Survival of the patients who started treatment with cervical, endometrial, and ovarian cancer in 2017 was analyzed by using the Kaplan–Meier, log–rank, and Wilcoxson tests. Results: Treatment was initiated in 2022 for 8039 patients with cervical cancer, 14 518 with endometrial cancer, 8524 with ovarian, tubal, and peritoneal cancer, 2360 with ovarian borderline tumors, and with the others (270 vulvar cancer, 179 vaginal cancer, 539 uterine sarcoma, 48 uterine adenosarcoma, 158 trophoblastic diseases). This clinicopathological information was summarized as the Patient Annual Report. The 5-year survival rates of the patients who initiated treatment in 2017 were as follows. For cervical cancer, the rates were 93.0%, 76.1%, 59.5%, and 28.3% for Stages I, II, III, and IV, respectively. For endometrial cancer, the rates were 94.9%, 88.8%, 72.7%, and 28.9% for Stages I, II, III, and IV, respectively. For ovarian cancer, the rates were 91.7%, 76.6%, 54.4%, and 45.2% for Stages I, II, III, and IV, respectively. Conclusion: The annual tumor report is an important survey that provides knowledge on gynecological malignancy trends in Japan.

• Access to Document (DOI)

腫瘍減量術を行わずPARP阻害薬維持療法にて3年以上無増悪生存を得られた高齢の進行卵巣癌2例

瀬古彩音，吉浜智子，落合大輔，坂巻智美，地阪光代，坂井健良，大木慎也，千代田達幸，山上 亘，田中 守

東京産科婦人科学会会誌 74 （ 4 ） 839 - 843 2025年10月

研究論文（学術雑誌）, 共著

胚移植困難症例に対して経子宮筋層胚移植（TMET）を実施した10症例（24移植周期）の検討

徳岡 旭，内田志穂，佐久間萌子，大岡令奈，祝井麻希，佐々木拓幸，上條慎太郎，内田明花，山田満稔，山上 亘，田中 守

東京産科婦人科学会会誌 74 （ 4 ） 797 - 804 2025年10月

研究論文（学術雑誌）, 共著, 査読有り

Potential New Tumors Associated with Hereditary Breast and Ovarian Cancer (HBOC)

Nakamura K, Masuda K, Seki T, Kitago M, Kosaka T, Goto Y, Yamada M, Misu K, Ono I, Kobayashi Y, Yamagami W

Keio J Med 74 （ 3 ） 158 - 161 2025年09月

研究論文（学術雑誌）, 共著

Hormone replacement therapy in female-specific cancer survivors: considerations beyond cancer cure

Yoshihama T, Yokota M, Aoki D, Yamagami W

Jpn J Clin Oncol 55 （ 9 ） 1000 - 1004 2025年09月

研究論文（学術雑誌）, 共著

Revision of quality indicators for cervical cancer and trend analysis of existing indicators in Japan

Kakuwa T, Rikitake R, Nagase S, Mikami M, Baba T, Kaneuchi M, Tokunaga H, Seino M, Muramatsu T, Yamagami W, Takehara K, Niikura H, Hirashima Y, Yoshino K, Ichinose Y, Kawata A, Higashi T

J Gynecol Oncol 36 （ 5 ） e78 2025年09月

研究論文（学術雑誌）, 共著

The Keio HBOC Center: A Model of Hereditary Breast and Ovarian Cancer Management

Kobayashi Y, Masuda K, Seki T, Kosaka T, Kitago M, Ono I, Misu K, Ueki A, Yoshihama T, Nagayama A, Yasumizu Y, Goto Y, Nakamura K, Yamada M, Yokota M, Uchida S, Takeuchi M, Funakoshi T, Yamagami W

Keio J Med 74 （ 3 ） 124 - 129 2025年09月

研究論文（学術雑誌）, 共著

Current Situation and Future Directions of Risk-reducing Salpingo-oophorectomy

Masuda K, Kobayashi Y, Seki T, Yoshihama T, Nakamura K, Goto Y, Yamada M, Nagayama A, Uchida S, Ono I, Misu K, Yokota M, Yamagami W

Keio J Med 74 （ 3 ） 158 - 161 2025年09月

研究論文（学術雑誌）, 共著

Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR-SCREEN-2 Study

Hashimoto T, Iida N, Nakamura Y, Nonomura N, Morizane C, Iwata H, Okano S,Yamagami W, Yamazaki N, Kadowaki S, Ueno M, Boku S, Oki E, Komatsu Y, Yuki S, Makiyama A, Ogata T, Takahashi N, Okano N, Nishina T, Sakamoto N, Kuwata T, Yamashita R, Shibuki T, Imai M, Fujisawa T, Bando H, Shitara K, Yoshino T

Cancer Sci 116 （ 8 ） 2218 - 2231 2025年08月

研究論文（学術雑誌）, 共著

Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial

Nishio S, Nishikawa T, Mori M, Kamiura S, Sumi T, Yunokawa M, Imai Y, Kondo E, Takehara K, Takano H, Kudaka W, Kado N, Yamagami W, Kato H, Nishino K, Usami T, Hamanishi J, Nii M, Takaya I, Okamoto A

Journal of gynecologic oncology 36 （ 4 ） e118 2025年07月

研究論文（学術雑誌）, 共著,  ISSN  2005-0380

• Access to Document (DOI)

卵巣性索腫瘍類似子宮腫瘍(uterine tumors resembling ovarian sex cord tumors; UTROSCT) 2例の検討

杉山紗耶，辻 浩介，金子奈穂美，福田崇晃，渡辺 隼，中村加奈子，野上侑哉，増田健太，木須伊織，田中 守，山上 亘

東京産科婦人科学会会誌 74 （ 3 ） 619 - 624 2025年07月

研究論文（学術雑誌）, 共著, 査読有り

Prognostic significance of para-aortic node metastasis in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis

Konno Y, Mayama M, Takehara K, Yokoyama Y, Suzuki J, Susumu N, Harano K, Nakagawa S, Nakanishi T, Yamagami W, Yoshihara K, Nomura H, Okamoto A, Aoki D, Watari H

J Gynecol Oncol 36 （ 4 ） e57 2025年07月

研究論文（学術雑誌）, 共著

High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target

Yoshimura T, Kamatani T, Ookubo A, Takahashi M, Itoh M, Ebisudani T, Masugi Y, Toyonaga T, Hamamoto J, Saotome K, Sakai K, Yoshihama T, Moritoki N, Shibata S, Yasuda H, Sato T, Sato TA, Aoki D, Yamagami W, Tsunoda T, Chiyoda T

Cancer research communications 5 （ 6 ） 1018 - 1033 2025年06月

研究論文（学術雑誌）, 共著

• Access to Document (DOI)

Advancing Precision Oncology: Whole-Exome Sequencing in Endometrial Cancer Liquid-Based Cytology

Takamatsu R, Nakamura K, Chiyoda T, Tsuji K, Kawano R, Yoshimi N, Yamagami W, Nishihara H

Arch Pathol Lab Med 149 （ 6 ） 561 - 567 2025年06月

研究論文（学術雑誌）, 共著